Substance / Medication

Trospium

Overview

Active Ingredient
trospium
RxNorm CUI
236778

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of xanomeline and xanomeline trospium in the treatment of cognitive impairment: A systematic review of preclinical and clinical trials.
Valentino Kyle, Shen Bianca, Waisman Bethany et al. · Eur Neuropsychopharmacol · 2026
PMID: 41418563Meta-Analysis
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis.
Fabiano Nicholas, Wong Stanley, Zhou Carl et al. · Eur Neuropsychopharmacol · 2025
PMID: 39724748Meta-Analysis
Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes.
Kishi Taro, Citrome Leslie, Sakuma Kenji et al. · Pharmacopsychiatry · 2025
PMID: 39880004Meta-Analysis
Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis.
Menegaz de Almeida Artur, Moraes Tamashiro Fernanda, Cavalcanti Souza Maria Eduarda et al. · J Psychiatr Res · 2025
PMID: 39637717Meta-Analysis
Clinical pharmacokinetics of trospium chloride.
Doroshyenko Oxana, Jetter Alexander, Odenthal Karl P et al. · Clin Pharmacokinet · 2005
PMID: 15966754Meta-Analysis
Safety and Efficacy of Trospium Chloride and Solifenacin in Stroke-Induced Neurogenic Lower Urinary Tract Dysfunction: A Randomized Controlled Trial.
Hajebrahimi Sakineh, Pourmohammad Ali, Konstantinidis Charalampos et al. · Neurourol Urodyn · 2025
PMID: 39469916RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Trospium (substance)
SNOMED CT
412604005
UMLS CUI
C0772089
RxNorm CUI
236778

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.